ABSTRACT
Background One of the adverse effects of anthracycline use is cardiotoxicity manifested as heart failure. The benefit of sacubitril/valsartan in patients with heart failure of ischemic origin has been demonstrated, but not due to toxicity. Our objective was to determine if there are protective effects of the use of sacubitril/valsartan in cardiotoxicity induced by anthracyclines.
Methods A bibliographic search was carried out in PubMed, Cochrane Library, LILACS, Scopus, EBSCO and Google Scholar. A systematic review and meta-analysis was performed to assess mean differences (MD) with 95% confidence intervals following the PRISMA Statement.
Results 558 published articles were found, of which three were submitted to analysis, with a total sample of 69 patients. With the use of sacubitril/valsartan there was an increase in the percentage of left ventricular ejection fraction (LVEF) [MD 6.78% (p < 0.001)], an increase in the percentage of global longitudinal strain of the left ventricle (LV-GLS) [MD 3.37 % (p < 0.001)], and decreased serum levels of NT-proBNP [MD −1003.64 pg/mL (p < 0.001)]; in addition, there was an increase in the distance traveled with the use of sacubitril/valsartan [MD 95.23 meters (p < 0.001)] compared to their baseline values, respectively.
Conclusions This meta-analysis suggests that there is a benefit from the use of sacubitril/valsartan in patients with heart failure related to the use of anthracyclines on ventricular remodeling and functional capacity. This is the first meta-analysis to our knowledge evaluating this effect. Randomized double-blind placebo-controlled clinical trials are required to confirm these findings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is a systematic review.
Funding Statement
The authors declare thah this work was not supported by pharmaceutical industry.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Protocol approved by the Research Committee of the General Hospital of Mexico
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Telephone number: +52 (55) 4718 8374 Email: felipe.israel.lopez.trejo{at}hotmail.com, Telephone number: +52 (55) 4354 8162 Email: danniibarrera03{at}gmail.com, Telephone number: +52 (55) 4797 955 Email: elias.noel.ac{at}gmail.com, Telephone number: +52 (55) 4185 6805 Email: jmoralesportano{at}gmail.com, Telephone number: +52 (55) 2106 8740 Email: alinemtz2{at}yahoo.es
Data Availability
There are no extraordinary data to be shown other than those mentioned in the manuscript.
